{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-24-000067","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.178564+00:00","generated_at":"2026-05-31T12:51:09.618973+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ligand Q2 revenue rises 57% to $41.5M; GAAP net loss $51.9M on $33.8M Primrose Bio writedown","bullets":["Total revenue $41.5M (+57% YoY); royalties $23.2M (+11%); Captisol $7.5M (+44%).","GAAP net loss from continuing ops $51.9M ($2.88/sh) vs income $2.3M ($0.13) YoY; adjusted net income $25.8M ($1.40).","Core adjusted net income $25.8M vs $11.7M YoY, excluding Viking stock sales and non-cash impairments.","2024 guidance reaffirmed: royalties $100-105M, total revenue $140-157M, core adj. EPS $5.00-$5.50.","Completed $100M APEIRON Biologics acquisition (July 8); credit facility expanded to $125M."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-24-000067","json":"https://secwatch.observer/filing/0000886163-24-000067.json","markdown":"https://secwatch.observer/filing/0000886163-24-000067.md","text":"https://secwatch.observer/filing/0000886163-24-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000067/0000886163-24-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000067/lgnd-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:51:09.618973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}